Emtricitabine (Emtriva)

08/01/2021 - "Patients with HIV infection were excluded, and patients treated with combination TDF/emtricitabine were analyzed separately from patients receiving only TDF. "
03/27/2018 - "Increasing prescription of TDF/emtricitabine for patients at risk of acquiring HIV has the potential to reduce new HIV infections."
01/01/2017 - "An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection."
09/01/2016 - "Selection of emtricitabine-resistant strains is mainly reported in individuals with an undiagnosed HIV infection using PrEP. "
01/01/2005 - "Emtricitabine: a review of its use in the management of HIV infection."

06/01/2004 - "Emtricitabine is a safe and effective option for HIV-1 infection in adults as part of a multidrug regimen. "
09/01/2005 - "Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine occurred in 23% of patients. "
09/01/2005 - "Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine."
01/09/2006 - "Posttreatment exacerbation of HBV infection developed in 23% of emtricitabine-treated patients. "
06/01/2004 - "Emtricitabine is an NRTI used to treat HIV-1 infection. "

01/02/2008 - "Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted."
01/01/2010 - "Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand."
01/02/2008 - "Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions. "
01/02/2008 - "Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection."
11/24/2011 - "Fixed dose combination of emtricitabine/tenofovir/efavirenz (ATRIPLAR) which has been approved by Food and Drug Administration shows promising results as far as safety and efficacy is concerned in TB/HIV co-infection patients, hence can be considered effective and safe antiretroviral drug in TB/HIV management for adult and children above 3 years of age."

07/01/2005 - "Based on these data, 200 mg emtricitabine once daily was chosen as the optimal dose for future hepatitis B studies."
07/01/2005 - "The aim of this study was to evaluate long term safety and antiviral activity of different doses of emtricitabine given once daily to patients chronically infected with hepatitis B. "
06/01/2002 - "Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection."
01/01/2016 - "The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B."
01/01/2016 - "The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B."

01/09/2006 - "A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B."
06/01/2002 - "These results support further clinical development of emtricitabine for the treatment of chronic hepatitis B infection."
07/13/2015 - "Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B."
10/01/2011 - "Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study."
05/01/2008 - "96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B."